Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 23, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - November 23, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/23/14 - Canada : Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer [TendersInfo (India)]
Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. Also, we are very pleased to be wo
11/23/14 - FDA Grants Orphan Drug Designation to Astellas for Isavuconazole for the Treatment of Invasive Candidiasis
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Astellas announced that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis. An FDA orphan drug designation provides several benefits to the sponsor including a seven-year period of market exclusi
11/23/14 - New Clinical Trials and Studies Study Findings Have Been Reported by Investigators at University of Alberta Hospital [Providing Rapid Out of Hospital...
New Clinical Trials and Studies Study Findings Have Been Reported by Investigators at University of Alberta Hospital. By a News Reporter-Staff News Editor at Heart Disease Weekly Current study results on Clinical Research have been published. The news correspondents obtained a quote from the research from the University of Alberta Hospital, "Pati
11/23/14 - Researchers at National Heart Lung and Blood Institute Report New Data on Clinical Trials and Studies (Reconciling the Divergent Findings from...
For more information on this research see: Reconciling the Divergent Findings from Clinical Trials and Observational Studies of Menopausal Hormone Therapy for Prevention of Coronary Heart Disease. Seminars in Reproductive Medicine, 2014; 32: 426-432. Seminars in Reproductive Medicine can be contacted at: Thieme Medical Publ Inc, 333 Seventh Ave, Ne
11/22/14 - "Methods of Inhibiting Tumor Growth by Antagonizing Il-6 Receptor" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor ZHANG, LI, filed on July 11, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Regeneron Pharmaceuticals, In
11/22/14 - Flagler company inks Chinese export deal [EMBIN (Emerging Markets Business Information News]
Nature's Nurse International, a Flagler Beach company, announced that it has entered into a partnership with Chinese pharmaceutical company Sinopharm, which has agreed to begin marketing its products in China beginning next month. The company's staff is made up of 11 independent contractors in Flagler Beach and Atlanta as well as three in Fiji, sai
11/22/14 - France : DLA Piper represents Neothetics in initial public offering [TendersInfo (India)]
DLA Piper advised Neothetics, Inc., a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, in the pricing of its initial public offering of 4,650,000 shares of its common stock at a public offering price of $14.00 per share. The San Diego- based DLA Piper team representing Neothetics was led by partners
11/22/14 - Generic drug prices skyrocket in past year [Chicago Tribune]
The 44- year-old piano tuner and guitar instructor from Elgin, who has health insurance, used to pay $20 for a three-month supply of his generic epilepsy drug as a member of Walgreen's Prescription Savings Club. But in the past year, the price of many generics is disconcertingly moving in the wrong direction, drawing the attention of Congress and p
11/22/14 - OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 21, 2014.{ nfg} OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics which target cancer stem cells, or tumor-initiating cells, presented data in two posters highlighting the company's translational research an
11/22/14 - Soaring generic drug prices draw Senate scrutiny [EMBIN (Emerging Markets Business Information News]
A Senate panel met Thursday to scrutinize the recent, unexpected trend among generic medicines, which usually cost 30 to 80 percent less than their branded counterparts. Bernie Sanders, who chairs the Senate Subcommittee on Primary Health and Aging. Sanders introduced a bill that would require generic drugmakers to pay rebates to the federal Medica
11/22/14 - Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment
Sprout Pharmaceuticals today announced positive preliminary results from a Phase 1 driving study, which demonstrate that women treated with flibanserin up to 200 mg at bedtime had no next-day impairment of driving ability. The data were presented at the 20 th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America in Miami.
11/22/14 - Tekmira Provides Key Highlights of Analyst and Investor Day in New York
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today an update from the Company's Analyst and Investor Day, which took place on November 21 in New York City. The Company announced its first regulatory filing, in the form of a Clinical Trial Application filed with Health Canada, to support its
11/22/14 - Testosterone treatment: Fountain of youth or heart attack risk? [The Indianapolis Star]
Nov. 22 It's almost predictable. First came the drug company ads aimed at older men. Feeling tired, irritable, lost your sex drive?
11/21/14 - "Borosilicate Glass Having Improved Hydrolytic Resistance for Preferred Use in the Pharmaceutical Sector" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Tratzky, Stephan; Kass, Christof; Eichholz, Rainer; Nass, Peter, filed on April 28, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent applicatio
11/21/14 - "The Price of Global Health" Tackles Worldwide Drug-Pricing Debate
Heated dialogue in recent months about the rising cost of prescription drug prices from cancer treatments to Gilead's new hepatitis C drug Harvoni has consumers, legislators and pharmaceutical leaders around the world questioning what it means to put a price on patient treatment and quality of care. And while drug pricing is one of the m
11/21/14 - Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Deutsche Bank BioFEST Conference in Boston. Aegerion Pharmaceuticals is a biopharmaceutical company...
11/21/14 - Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer; Patient recruitment in line to secure expected interim analysis in H1 2015
Release date- 20112014- Quebec City, Canada,- Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometr
11/21/14 - Anti-Migraine Drugs Market Research Reports And Industry Analysis 2014-19
In the coming years, the market for anti-migraine drugs is anticipated to witness several launches of new generic migraine drugs that will steadily increase the drug-treatment levels and rate of diagnosis paving a sustainable path to an annual global growth of the overall anti-migraine drugs market. View Full Report at...
11/21/14 - Aprecia Pharmaceuticals Assigned Patent for Three-dimensional Printing System and Equipment Assembly
ALEXANDRIA, Va., Nov. 21 Aprecia Pharmaceuticals, Langhorne, Pennsylvania, has been assigned a patent developed by six co-inventors for a "three-dimensional printing system and equipment assembly." The co-inventors are Jaedeok Yoo, Princeton, New Jersey, Thomas J. Bradbury, Yardley, Pennsylvania, Thomas J. Bebb, Pottstown, Pennsylvania, James Isk
11/21/14 - Astellas aims to introduce cancer medicines in UAE [EMBIN (Emerging Markets Business Information News]
The Japanese drug maker Astellas is looking to introduce one of its best-selling cancer medicines in the UAE ? and to start manufacturing drugs in the country by 2019.. From its Dubai office, which opened on Thursday, it plans to market its products in the Middle East, North Africa and sub- Saharan Africa. While most of its medicines in the
11/21/14 - Avaxia Biologics Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted antibody therapeutics for gastrointestinal diseases, announced today that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which...
11/21/14 - Bacterial Pneumonia & Sepsis Clinical Trials Market Review H2 2014
This report provides elemental information and data relating to the clinical trials on Bacterial Pneumonia& Sepsis.Dallas, TX 11/21/2014 The clinical trial report, Bacterial Pneumonia Global Clinical Trials Review, H2, 2014 "provides data on the Bacterial Pneumonia clinical trial scenario. The report Bacterial Pneumonia Global Clinical
11/21/14 - BioSpecifics Technologies Corp. Announces New Data on XIAFLEX for Peyronie's Disease Presented at SMSNA Scientific Meeting
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced new data on XIAFLEX for the treatment of Peyronie's disease from the Phase 2 and the pivotal Phase 3 IMPRESS trials, presented by BioSpecifics' licensee, Auxi
11/21/14 - Ceapro Appoints World Renowned Health And Disease Management Expert, William W. Li, M.D. To Board Of Directors [Global Data Point]
Through his work at the Angiogenesis Foundation, he has developed a unique social enterprise model based on international collaborations with leading medical academic centers, biopharmaceutical companies and government agencies, including the National Institutes of Health, National Cancer Institute and the Food and Drug Administration.
11/21/14 - Celgene Receives Positive CHMP Opinion for OTEZLA (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
BOUDRY, Switzerland Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency s Committee for Medicinal Products for Human Use has adopted a positive opinion for OTEZLA , the Company s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications:
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415